Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Berger

Showing results (661-670 of 774) with videos related to

Pageof 78
Sort By:
American Heart Journal|July 12, 2011
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialJeffrey S Berger, Deepak L Bhatt, P Gabriel Steg, et al.
JACC. Cardiovascular Interventions|July 26, 2023
Ad Hoc Percutaneous Coronary Intervention in Stable Patients With Multivessel or Unprotected Left Main DiseaseEdward L Hannan, Ye Zhong, Kimberly Cozzens, et al.
Journal of Geriatric Cardiology : JGC|April 28, 2021
Hybrid coronary revascularization <i>vs</i>. percutaneous coronary interventions for multivessel coronary artery diseaseEdward L Hannan, Yi-Feng Wu, Kimberly Cozzens, et al.
The Canadian Journal of Cardiology|October 5, 2021
The Association of Socioeconomic Factors With Percutaneous Coronary Intervention OutcomesEdward L Hannan, Yifeng Wu, Kimberly Cozzens, et al.
Circulation|June 22, 2000
Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI InvestigatorsF Feit, M M Brooks, G Sopko, et al.
Journal of the American College of Cardiology|November 13, 2001
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trialW B Batchelor, K W Mahaffey, P B Berger, et al.
Circulation|November 26, 2009
Smoking, clopidogrel, and mortality in patients with established cardiovascular diseaseJeffrey S Berger, Deepak L Bhatt, Steven R Steinhubl, et al.
Journal of the American College of Cardiology|December 27, 2014
Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending diseaseEdward L Hannan, Ye Zhong, Gary Walford, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 12, 2011
Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trialAhmed A Khattab, Gjin Ndrepepa, Stefanie Schulz, et al.
Circulation|June 3, 2010
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialPeter B Berger, Deepak L Bhatt, Valentin Fuster, et al.
Pageof 78

Showing results (661-670 of 774) with videos related to

Sort By:
Pageof 78
American Heart Journal|July 12, 2011
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialJeffrey S Berger, Deepak L Bhatt, P Gabriel Steg, et al.
JACC. Cardiovascular Interventions|July 26, 2023
Ad Hoc Percutaneous Coronary Intervention in Stable Patients With Multivessel or Unprotected Left Main DiseaseEdward L Hannan, Ye Zhong, Kimberly Cozzens, et al.
Journal of Geriatric Cardiology : JGC|April 28, 2021
Hybrid coronary revascularization <i>vs</i>. percutaneous coronary interventions for multivessel coronary artery diseaseEdward L Hannan, Yi-Feng Wu, Kimberly Cozzens, et al.
The Canadian Journal of Cardiology|October 5, 2021
The Association of Socioeconomic Factors With Percutaneous Coronary Intervention OutcomesEdward L Hannan, Yifeng Wu, Kimberly Cozzens, et al.
Circulation|June 22, 2000
Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI InvestigatorsF Feit, M M Brooks, G Sopko, et al.
Journal of the American College of Cardiology|November 13, 2001
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trialW B Batchelor, K W Mahaffey, P B Berger, et al.
Circulation|November 26, 2009
Smoking, clopidogrel, and mortality in patients with established cardiovascular diseaseJeffrey S Berger, Deepak L Bhatt, Steven R Steinhubl, et al.
Journal of the American College of Cardiology|December 27, 2014
Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending diseaseEdward L Hannan, Ye Zhong, Gary Walford, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 12, 2011
Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trialAhmed A Khattab, Gjin Ndrepepa, Stefanie Schulz, et al.
Circulation|June 3, 2010
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialPeter B Berger, Deepak L Bhatt, Valentin Fuster, et al.
Pageof 78